Mediwound (NASDAQ:MDWD) will be announcing its earnings results before the market opens on Monday, March 19th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Shares of Mediwound (MDWD) traded up $0.05 during trading hours on Wednesday, reaching $4.30. The company’s stock had a trading volume of 4,561 shares, compared to its average volume of 28,067. The company has a market cap of $114.95, a P/E ratio of -6.72 and a beta of 0.15. Mediwound has a 52-week low of $3.56 and a 52-week high of $8.25.
A number of research analysts have issued reports on MDWD shares. SunTrust Banks set a $9.00 price objective on Mediwound and gave the company a “buy” rating in a research note on Thursday, November 16th. Zacks Investment Research downgraded Mediwound from a “buy” rating to a “hold” rating in a research note on Tuesday, November 21st. ValuEngine upgraded Mediwound from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 25th. Finally, Oppenheimer set a $10.00 price objective on Mediwound and gave the company a “buy” rating in a research note on Friday, December 8th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $9.13.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.